Antibody Screening - Unravelling the full potential of entire immune repertoires (millions of B cells) VERAXA´s unique platform can combine the assessment of antibody binding with its functional capabilities in 1 single screening step, using a proprietary droplet-based microfluidic screening workstation.


Biotechnology

Veraxa Biotech

Christoph Antz

Yasemin Doeger

Heinz Schwer Ph.D.

Marian Weiss

Anna Pryszlak

Torsten Bürgermeister

Edward A. Lemke

Steffen Runz

Paul F. Sauter

Christine Köhler

Michael Ruppert

Christoph A. Merten

Lars Hufnagel

Research and Development

Leadership Team

Teams at Veraxa Biotech

Research and Development

Leadership Team